Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-22-000035

President and CEO sold 2,719 shares at $37.55 ($102,104)

  • President and CEO acquired 70,749 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Watts Ryan J. President and CEO 2022-02-09 Sale −2,719 $37.55 $102,104 2,119,442 I: show line 1 in the form
Watts Ryan J. President and CEO 2022-02-10 Option exercise +64,631 $5.28 $341,252 254,522 D: show line 2 in the form
Watts Ryan J. President and CEO 2022-02-10 Option exercise +6,118 $9.60 $58,733 260,640 D: show line 3 in the form
Open-market sales · 2,719 sh · avg $37.55 · $102,104

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Watts Ryan J. President and CEO 2022-02-10 Option exercise · Stock Option (right to buy) −64,631 0 D: show line 4 in the form
Watts Ryan J. President and CEO 2022-02-10 Option exercise · Stock Option (right to buy) −6,118 0 D: show line 5 in the form
Loading xslF345X03/wf-form4_164461792855991.xml…